HYDERABAD: Japanese pharma giant Takeda has entered into a strategic partnership with Hyderabad-based biopharma player Biological E Limited (BE), to manufacture up to 50 million doses of Takeda ...

The US regulator has started a priority, six-month review of Takeda's dengue fever vaccine TAK-003 – tipped as a potential blockbuster product – making a decision likely in the first half of 2023.

HYDERABAD: Takeda and Biological E Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, on Tuesday, announced a strategic partnership to accelerate access to QDENGA (Dengue ...

India experiences the world’s absolute burden of at least 11 NTDs, including hookworm, dengue, lymphatic filariasis, leprosy, ...

Why is there still no dengue vaccine in the country?” This was the question posed by Union of Local Authorities of the Philippines president and Quirino governor Dax Cua to the Department of Health, a ...

Ecuador's Health Ministry confirmed Thursday that the South American country was going through a dengue epidemic.

The drug, produced by the laboratory Takeda, targets “dengue virus ... Salta will be the first province in the country to apply the vaccine against dengue. The provincial government will buy ...

Takeda had hoped that Eohilia would be the ... The drugmaker has had mixed results from Wave1, with approvals for dengue fever vaccine Qdenga and post-transplant cytomegalovirus (CMV) therapy ...

WHO clears Takeda's dengue vaccine May 15, 2024 The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's therapy to treat adult patients with a hormone disorder by three ...